QLife (QLIFE) Q4 2024 earnings summary

Executive summary

• Transitioned from R&D to commercialization, focusing on sales and marketing with three tech platforms: General Health, Rare Diseases, and Home-Hospital biomarkers.

• Strengthened partnership with Hipro Biotech, enabling CE-IVD marked product launch and operational production in China.

• Signed LOI with a top-20 global pharma company for potential collaboration and launched a rights issue to secure 12 months of operations.

Financial highlights

• Q4 2024 revenue was KSEK 50, up from KSEK 30 in Q4 2023; full-year revenue KSEK 89, down from KSEK 244 in 2023.

• Q4 EBITDA improved to KSEK -7,721 from KSEK -86,903; net loss narrowed to KSEK -7,106 from KSEK -111,545 year-over-year.

• Cash flow in Q4 was KSEK 2,628, reversing a negative KSEK -6,096 in Q4 2023; cash reserve at year-end was KSEK 2,715.

• Shareholders' equity at year-end was KSEK -1,429, up from KSEK -23,123 at end of 2023.

• Number of employees reduced to 3 from 13 in Q4 2023.

Outlook and guidance

• Aims to reach profitability by Q1 2026, targeting a PKU self-testing audience of 50,000 and full-scale commercialization post-UK regulatory approval.

• Proceeds from rights issue (up to SEK 11.8 million) will fund sales, marketing, and commercialization efforts over the next 12 months.

• Expects to expand partnerships and launch additional products in the EU and globally.